



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C07K 17/00, 17/02, 17/06 A61K 39/385	<b>A1</b>	<b>(11) International Publication Number:</b> WO 91/03494 <b>(43) International Publication Date:</b> 21 March 1991 (21.03.91)
<b>(21) International Application Number:</b> PCT/US90/04308 <b>(22) International Filing Date:</b> 31 July 1990 (31.07.90) <b>(30) Priority data:</b> 399,081 28 August 1989 (28.08.89) US <b>(71) Applicant:</b> PIERCE CHEMICAL COMPANY [US/US]; 3747 North Meridian Road, Rockford, IL 61105 (US). <b>(72) Inventors:</b> DOMEN, Patricia, L. ; 230 Evelyn Avenue, Apartment 4, Loves Park, IL 61111 (US). HERMAN- SON, Greg ; 6171 Basin Drive, Loves Park, IL 61111 (US). <b>(74) Agent:</b> CAHN, Maurice, U.; Leydig, Voit & Mayer, 700 Thirteenth Street, N.W., Suite 300, Washington, DC 20005 (US).		<b>(81) Designated States:</b> AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent)*, DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (Eu- ropean patent), SE (European patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> CATIONIZED CARRIERS FOR IMMUNOGEN PRODUCTION  <b>(57) Abstract</b>  A conjugate of a protein carrier and an antigen is disclosed. The carrier protein is cationized and the conjugate has enhanced immunogenic properties over those of the antigen alone. Cationization can be accomplished by derivatization of native carboxyl groups on the protein with an alkyl diamine, e.g. ethylene diamine, resulting in the formation of side chain aminoalkylamide groups, e.g. aminothylamide.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

## CATIONIZED CARRIERS FOR IMMUNOGEN PRODUCTION

Technical Field

The present invention relates to the production of antibodies and, more particularly, to conjugates  
5 which have an enhanced ability to raise antibodies after injection into an animal.

Background Art

Immunization protocols involve the injection of a substance capable of stimulating an immunogenic  
10 response into an animal and, after some period of time, bleeding the animal and recovering the antibodies so produced. The immunogenic substance, termed "an antigen," is generally dissolved or  
15 as Freund's Adjuvant, alum, etc., to enhance the immune response. Booster shots are also employed after the initial injection in order to enhance the response.

Even with the use of adjuvants and boosters,  
20 there are certain substances with potential antigenic characteristics which are simply too small to induce an antibody response when directly injected into an animal. Peptides, mycotoxins or other small molecules, termed "haptens," are  
25 examples of such substances. To utilize these as immunogenic substances, it is customary to conjugate, i.e. cross-link, them to a carrier protein such as bovine serum albumin (BSA) prior to injection. Coupling of the hapten to the protein is  
30 accomplished by reaction of the hapten with the functional groups of the protein.

As discussed by Chu, et al., in "Journal of Immunological Methods" 55 (1982) 73-78, the amount of hapten conjugated to each mole of carrier protein  
35 plays an important role in determining the quantity

and specificity of the antibody response to the conjugate. In this instance, a large excess of mycotoxin was found to be necessary in the coupling reaction to yield a conjugate with the appropriate  
5 degree of substitution to function as a good antigen.

What Chu, et al., disclosed in the previously cited article is that modification of BSA with ethylene diamine gave an increase in the number of  
10 amino groups present on the carrier and thus enhanced the coupling efficiency of the hapten, mycotoxin. In turn, it is disclosed that the use of this resultant conjugate produces substantially higher antibody titers more rapidly than when the  
15 unmodified carrier conjugate was used.

Concerning substances which are themselves immunogenic without coupling to a carrier, e.g. BSA, researchers at the University of Cincinnati College of Medicine have published a series of papers  
20 reporting on how the response can be improved by cationizing the antigens prior to animal injection. The papers are as follows:

1. Muckerheide, et al., "The Journal of Immunology," 138, 833-837 (1987).
- 25 2. Muckerheide, et al., "The Journal of Immunology," 138, 2800-2804 (1987).
3. Domen, et al., "The Journal of Immunology," 139, 3195-3198 (1987).
4. Apple, et al., "The Journal of  
30 Immunology," 140, 3290-3295 (1988).

As illustrated in these articles, cationization of BSA is achieved by substituting native anionic side chain carboxyl groups with cationic amino ethylamide groups. As with Chu, this is achieved by reacting  
35 BSA with ethylenediamine.

While the articles in the "Journal of Immunology" identified above establish the fact that

a large molecule like BSA can be made an even more potent immunogen by cationization, to carry this concept over to other antigens may be time consuming and difficult. There are a number of proteins which the scientific community is interested in evaluating for immunogenic characteristics, and the protocol for cationizing each of them to achieve optimum enhancement is unique. In addition, direct cationization of some antigens may destroy or modify their native antigenic determinants, thus rendering them useless.

#### Disclosure of Invention

Having the foregoing in mind, the present invention provides a conjugate of a protein carrier and an antigen, said conjugate having enhanced immunogenic properties over those of the antigen alone. The carrier useful in the present invention is a protein which has been cationized. Preferably, cationization is accomplished by derivatization of native carboxyl groups on the protein with an alkyl diamine, e.g. ethylene diamine, resulting in the formation of side chain aminoalkylamide groups, e.g. aminoethylamide. Other amine containing compounds capable of introducing a positive charge on a protein can also be used so long as they do not sterically hinder conjugation to the antigen or adversely alter the antigenic character of the conjugate. As to the use of alkyldiamines, those having straight chain alkyl groups with 2-4 carbon atoms are considered most useful.

A protein cationized as described above will have enhanced immunogenic properties over that of the native protein. The use of such a protein as a carrier in preparing immunogen conjugates results in a complex where the enhanced immunogenic properties of the cationic carrier are transferred to the covalently coupled antigen, thereby producing a

greater immune response toward the antigen.

A remarkable aspect of the present invention is that a cationized protein can be used as a carrier for large molecules that are immunogenic by themselves. This is a novel concept because, under normal circumstances, immunization with two immunogenic substances, either cross-linked or separate, produces only undesirable results. The second substance only serves to contaminate the system and potentially reduce the response to the first, and vice versa.

Therefore, there are distinct advantages to using a conjugate prepared in accordance with this invention. Immunization with the conjugate elicits an immune response to the antigen greater than that observed when the antigen is used alone. In many instances, the use of conjugates described in this invention may eliminate the need for booster immunizations. The enhanced immunogenicity of the cationized carrier is transferred to the antigen coupled to it without altering the native antigenic determinants of the antigen. The use of the cationized carrier eliminates the necessity for separately characterizing the optimum cationization protocol for each antigen, providing one exists.

Cationization of the protein carrier raises its isoelectric point and the extent of cationization should be such that when the protein is combined with the antigen of interest, the resulting conjugate has an isoelectric point (pI) greater than the antigen alone. Preferably the pI of the conjugate is about 7.5 to about 11. Great enhancement in immunogenicity is achieved with conjugates having a pI of 7.5 or more. Conjugates having a pI above about 11 may be toxic and, accordingly, would not ordinarily be useful. Cationized protein carriers having a pI of at least

about 8 and less than about 12 have been found to be most useful.

Cationization of the protein carrier by forming the aminoalkylamide derivative thereof can be accomplished by known techniques such as illustrated in the above reference to Chu, et al., and the "Journal of Immunology" articles. In general, the carboxyl groups of the protein are activated by reaction with, for example, a water soluble carbodiimide followed by reaction with a diamine. Purification of the cationized protein is generally accomplished by dialysis against deionized water.

As with preparation of the cationized protein, conjugation thereof with an antigen of interest can be accomplished by known methods. The objective is to effectively conjugate antigen to the cationized carrier while minimizing the amount of polymerization so that the resulting conjugate is soluble at a physiological pH, i.e., about 7.5. As with the cationization reaction described above, conjugation can be accomplished using carbodiimide mediation for amide formation between the respective amino and carboxylic groups of the antigen and cationized protein. Alternatively, conjugation can be accomplished through the use of cross-linking reagents. These compounds usually have at least two reactive portions capable of covalently coupling to specific functional groups on proteins or other molecules. An illustration of this technique is described in Example VI where sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate) is used to conjugate arginine vasopressin to cationized BSA (cBSA). In this case, one reactive portion of the cross-linker (the NHS-ester end) reacts with available primary amines on cBSA while the other reactive group (the maleimide end) is used to couple a peptide through

its reduced sulfhydryl.

In addition to these compounds, alternate cross-linking reagents useful for this type of protein conjugation include dimethyl suberimide (DMS), glutaraldehyde, and m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). There are also many other similar cross-linkers which can be used to successfully conjugate a cationic carrier to an antigen. See Handbook and General Catalogue of Pierce Chemical Company, Rockford, Illinois (1989).

#### Brief Description of Drawings

Figs. 1 and 2 illustrate the immunogenic response in mice to the injection of various conjugated or unconjugated antigens.

#### Modes for Carrying Out the Invention

The following examples illustrate the present invention. All parts and percentages are by weight unless otherwise indicated.

##### Example I

This example illustrates the protocol for the preparation of cationized bovine serum albumin (cBSA) which is useful as a cationized protein carrier.

1. 6.7 ml of ethylenediamine (EDA) was added to 50 ml of 0.1 M MES (2-(N-morpholino) ethane sulfonic acid) buffer, pH 4.75. The pH was readjusted with concentrated HCl to pH 4.75 and cooled in an ice bath to ambient temperature (19-24°C) to prevent excess fuming.

2. Bovine serum albumin (500 mg) was dissolved in 2.5 ml of MES buffer (pH 4.75) and added to the above EDA solution.

3. Next, 180 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) was added with stirring.

4. The reaction was continued for 60 minutes at room temperature.



5. At the end of 1 hour, the reaction was quenched with 3 ml of 4 M sodium acetate, pH 4.75.

6. The solution was then dialyzed exhaustively against D.I. water (4 days, 5 changes, 20 liters each) to remove excess reagents.

7. The salt-free preparation of CBSA was finally lyophilized and stored at 4° C.

The degree of cationization, in terms of pI, of the protein carrier prepared above is determined by isoelectric focusing using the following procedure:

1. The mold for a LKB Multiphor system was prepared as described in the instruction manual.

2. A commercially available (Amresco) mixture of acrylamide (30%) and N,N'-methylenebisacrylamide (1%) was used as a stock solution. The gel was prepared as follows:

Acrylamide/Bis 20 ml  
Glycerol (87% v/v) 7 ml  
LKB ampholine pH 9-11 3 ml  
Distilled water 30 ml  
De-gas for 10 minutes.

Ammonium persulphate 2 ml  
(1% w/v)  
Mix by swirling.  
Fill the mold completely.  
Allow gel to polymerize.

3. A template was placed on the cooling plate of the Multiphor with a thin film of Tween 20 in between. The mold was dismantled and the gel on the 1 mm supporting plate was placed on the template with a thin film of Tween 20 in between.

4. The electrode strips were soaked with 1 M NaOH (cathode) or 1 M H<sub>3</sub>PO<sub>4</sub> (anode) and applied to the gel surface.

5. Pieces of filter paper were evenly spaced on the gel, using the template as a guide, about 1 cm from the anode. The samples were applied in 15 µl aliquots at a concentration of 6 mg/ml.

6. The electrode holder and lid were

positioned and the unit connected to a power supply. The gel was run at 25 W constant power, at 10° C, with 63 mA of current (initial setting) and 1360 volts (final reading) for 70 minutes.

5           7. The lid and electrode holder were removed. The sample application strips were removed with forceps. The pH of the gel was measured at 1 cm intervals using a surface electrode (Orion) and a standard curve was generated.

10           8. The apparatus was reassembled and the gel was refocused for 10 minutes.

          9. The unit was disassembled and the gel on the supporting glass plate was placed in fixing solution (50% ethanol and 5% acetic acid) for 30  
15 minutes.

          10. The gel was transferred into destaining solution (10% ethanol and 10% acetic acid) for 5 minutes.

          11. The gel was stained in Coomassie Blue  
20 staining solution for 10 minutes.

          12. The gel was destained overnight.

          13. The migration distance for each protein was measured and pI determined by reading from the standard curve.

25           The pI of the cationized protein carrier prepared in Example I was 7.7-9.7.

#### Example II

          This example illustrates the protocol for preparing a conjugate of a high molecular weight  
30 antigen (ovalbumin) and a cationized protein carrier.

          1. Dissolve 6 mg of cBSA, prepared as described in Example I, 6 mg of ovalbumin, and 2.5 mg EDC in 3 ml of MES buffer, pH 4.75.

35           2. Stir the reaction for 60 minutes at room temperature.

          3. The reaction mixture now containing the

conjugate of ovalbumin (OVA) and cBSA was then quenched with 35 ul of 4 M sodium acetate, pH 4.75, per ml of conjugate solution.

4. The conjugate was desalted by dialysis  
5 against PBS, pH 7.4 (0.01 M sodium phosphate, 0.15 M NaCl).

5. The dialyzed solution was lyophilized and stored at 4° C.

The pI of the conjugate prepared in this  
10 Example was 7.9-8.6, as determined by the procedure set forth in Example I.

#### Example III

This Example describes the use of the conjugate prepared in Example II, as well as the use of other  
15 antigens. The antigens used were (a) the OVA-cBSA conjugate prepared in Example II, (b) an OVA-native bovine serum albumin conjugate (OVA-nBSA) prepared by the basic protocol set forth in Example II using nBSA rather than cBSA, and (c) just OVA. To  
20 standardize for the amount of antigen injected, 20 micrograms of OVA were injected and 40 micrograms of each conjugate.

Mice were immunized by intraperitoneal (i.p.) injection of antigen mixed with an equal volume of  
25 alum (2.25 mg) as adjuvant. On day 28, half of the animals received a boost identical to the primary immunization. The immunized mice were bled periodically through the retro orbital plexus. The specific antibody response, expressed as percent of  
30 enhancement compared to the response to unconjugated OVA was determined by an enzyme linked immunosorbant assay (ELISA). Ferguson, T.A., T. Peters, Jr., R. Reed, A. J. Pesce and J. G. Michael. 1983.

Immunoregulatory properties of antigenic fragments  
35 from bovine serum albumin. Cell. Immunol. 78:1-12.

The results of immunization with the antigens

identified in this Example are illustrated in Figure 1. As shown in Figure 1A, the use of the conjugate of the present invention (OVA-cBSA) for primary immunization results in a substantially greater production of antibody than either OVA alone or the conjugate, OVA-nBSA. The anti-OVA response in mice immunized with the OVA-cBSA conjugate is enhanced by 100% (day 36) and 250% (day 49) the response of animals immunized with OVA alone. In contrast, rather than being enhanced, the anti-OVA response in mice immunized with the non-cationized OVA-nBSA conjugate is actually slightly lower at times than the response to OVA alone. As seen in Figure 1B, the pattern of enhancement with the cationized carrier is maintained following a boost. The results shown in Figure 1 indicate that covalently coupling an antigen to a cationized protein carrier produces an enhanced immune response toward the antigen.

#### Examples IV and V

Example III was repeated except that the antigens Human IgG (Examples IV) and Fetuin (Example V) were used in place of OVA. The conjugates of these antigens with cBSA had pI's of 7.85-8.92 and 7.88-8.17, respectively. As with the conjugate of Example III the conjugates of these Examples yielded an enhanced immune response compared with the antigen alone.

The foregoing Examples demonstrate that a conjugate of a cationized protein carrier and antigen produces an enhanced immune response toward the antigen. The same phenomena is observed when a cationized protein is coupled to a hapten which by itself is not immunogenic because of its small size. As indicated previously, with haptens, it is necessary to couple them to a larger carrier molecule such as a protein to elicit an immunogenic

response. As opposed to antigens which have a molecular weight of about 5,000 and above, haptens have a molecular weight of less than about 5,000. Molecular weight can be determined by polyacrylamide gel electrophoresis using known molecular weight standards as markers.

Thus, in accordance with a further aspect of the present invention, a conjugate of a cationized protein carrier and a hapten is provided. By using a cationized protein carrier to form the conjugate with the hapten, an enhanced immunogenic response to the hapten can be obtained, compared to the response obtained using the non-cationized form of the protein as the carrier. This phenomena is illustrated in the following Example VI.

#### Example VI

This Example illustrates the preparation of a conjugate of a hapten, the peptide arginine vasopressin, and the protein carrier of Example I.

For coupling the peptide to the carrier, the peptide was first activated by reaction with sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate). The compound is a cross-linker which has an NHS-ester for amine coupling to the carrier protein and a terminal maleimide group for coupling to sulfhydryl groups of peptides.

Arginine vasopressin is a representative peptide that is a readily available, naturally occurring, disulfide containing molecule. The disulfide groups of the peptide were reduced with an immobilized reductant prior to conjugating to the cBSA or nBSA.

The protocol for preparation of the conjugates is as follows:

A. Activation of cBSA and nBSA with Sulfo-SMCC:

1. 20 mg of nBSA (Pentex Grade, 5 times recrystallized, Miles Laboratories, Inc.) and cBSA (prepared as in Example I) were dissolved in 1.0 ml of 10 mM sodium phosphate, pH 7.0 in separate test tubes.

2. The solutions were added to separate tubes containing 5.0 mg sulfo-SMCC and vortex mixed until dissolved. The solution containing cBSA appeared hazy while the nBSA solution remained clear.

3. The reactions were allowed to continue for 1 hour at room temperature.

4. Two 15 ml desalting columns containing acrylamide gel (exclusion limit M.W. 5000) were equilibrated with 0.1 M ammonium bicarbonate, pH 6.0.

5. The maleimide-activated proteins were applied to the columns and eluted using the same buffer while taking 2 ml fractions. Those fractions containing protein (\*) were pooled and freeze-dried.

<u>Fraction</u>	<u>cBSA</u>	<u>nBSA</u>
1	.003	.036
2	.004	.021
3	.076	*2.867
4	*>	*>
5	.944	.780
6	2.217	>

#### B. Coupling of Arginine Vasopressin to Maleimide-Activated Proteins:

1. 5 mg of arginine vasopressin (AV;Sigma) was dissolved in 1.25 ml of PBS, pH 7.6, making a 4 mg/ml solution.

2. 1.0 ml of the above AV solution was applied to a 2.0 ml immobilized lipoic acid column to reduce the disulfides of the peptide.

3. 3 mg of lyophilized sulfo-SMCC  
activated proteins (both cBSA and nBSA) were  
dissolved in 1 ml of the immobilized lipoic  
acid column eluate which contained the reduced  
arginine vasopressin.

4. Conjugation was carried out with  
overnight incubation at room temperature  
without stirring.

5. Unconjugated peptide was removed by  
desalting using a 15 ml desalting column  
equilibrated with PBS, pH 7.0 (without azide).

6. Fractions containing protein were  
pooled and freeze-dried.

#### Example VII

Mice were immunized and bled as described in  
Example III. With the peptide, however, 100  
micrograms of conjugate were used. After a 49 day  
bleed, the mice were boosted with an immunization  
identical to the first.

The antibody response was determined as  
described in Example III with the response being  
expressed as a  $\mu\text{g/ml}$ . The response to the arginine  
vasopressin conjugates is shown in Figure 2. The  
early response to both the cBSA and nBSA conjugates  
is similar. After the boost, however, there is a  
two-fold enhancement with the cationized carrier.

In addition to peptide conjugates, the immune  
response of other carrier-hapten conjugates can be  
enhanced by using cationized protein as the carrier.  
Examples include conjugates of cationized protein  
and the following haptens: lipids, carbohydrates,  
nucleic acids and mycotoxins.

While this invention has been described and  
illustrated with respect to certain preferred  
embodiments thereof, it is not to be limited to  
those embodiments. Rather, the invention is as  
described in the appended claims.

Claims

1. A physiologically soluble conjugate of a carrier and an antigen, said carrier being a cationized protein and said conjugate being capable of eliciting an immune response to said antigen which is greater than that to the antigen alone.
2. The conjugate of Claim 1 wherein the antigen has a molecular weight of 5,000 or more.
3. The conjugate of Claim 2 wherein the cationized protein has an isoelectric point above about 8.
4. The conjugate of Claim 3 wherein the carrier is cationized serum albumin, said cationization being achieved by formation of aminoalkyl amide groups.
5. The conjugate of Claim 4 having a pI of 7.5-11 wherein the carrier is cationized bovine serum albumin and said aminoalkyl amide groups are aminoethyl amide groups.
6. A physiologically soluble conjugate of a carrier and hapten selected from peptides, lipids, carbohydrates and nucleic acids, said carrier being a cationized protein and said conjugate being capable of eliciting an immune response to said hapten which is greater than that of the hapten conjugated to the non-cationized form of the protein.
7. The conjugate of Claim 6 wherein the cationized protein has an isoelectric point above about 8.
8. The conjugate of Claim 7 wherein the carrier is a cationized serum albumin, said cationization being achieved by formation of aminoalkyl amide groups.
9. The conjugate of Claim 8 having a pI of 7.5-11 wherein the carrier is cationized bovine serum albumin and said aminoalkyl amide groups are



aminoethyl amide groups.

1/2

FIG. 1A




FIG. 1B





FIG. 2



# INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/04308

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) <sup>3</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 IPC(5): C07K 17/00, 17/02, 17/06; A61K 39/385  
 US Cl: 530/403, 404, 405, 406; 424/88

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>4</sup>

Classification System | Classification Symbols

U.S. 530/403, 404, 405, 406, 363, 408, 409, 410; 424/88

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched <sup>5</sup>

Computer Search Files: file CA and APS

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>14</sup>

Category <sup>6</sup>	Citation of Document, <sup>15</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>14</sup>
<u>N</u> <u>Y</u>	Journal of Immunological Methods, Volume 55, issued 1982, F. S. Chu <u>et al.</u> , "Ethylene diamine modified bovine serum albumin as protein carrier in the production of antibody against mycotoxins", see pages 73-78, especially pages 73-75 and 78.	<u>1, 6-9</u> <u>2-5</u>
<u>Y</u>	J. Clin. Invest., volume 69, issued February 1982, W. A. Border <u>et al.</u> , "Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen", see pages 451-461, especially page 454.	3-5, 7-9
<u>Y</u>	US, A, 4,769,237 (BITTLE <u>et al.</u> ) 06 September 1988, see columns 3, 15, 21 and claim 18.	1, 6-9
<u>Y</u>	US, A, 4,384,995 (STEVENS) 24 May 1983, see columns 20 and 36, lines 1-10.	1-9

<sup>6</sup> Special categories of cited documents: <sup>13</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search <sup>1</sup>

21 September 1990

International Searching Authority <sup>1</sup>

ISA/US

Date of Mailing of the International Search Report <sup>2</sup>

19 DEC 1990

Signature of Authorized Officer <sup>10</sup>

Kay K. Kim

*Kay K. Kim*

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

J. Immunol. Methods, Volume 87, issued 1986, A. J. Pesce et al., "Cationic Antigens-Problems associated with measurement by Elisa", see pages 21-27, especially 21-22.

1-9

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_, because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out<sup>1</sup>, specifically:
  
3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

Claims 1-9 encompass distinct happen represented by the following: 1) peptides; 2) lipids; 3) carbohydrates; and 4) nucleic acids.

(Continue to attachment).

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
  
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
  
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.